TTP 399

Drug Profile

TTP 399

Alternative Names: GK1-399; TTP-399

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TransTech Pharma
  • Developer vTv Therapeutics LLC
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Phase I/II Type 1 diabetes mellitus

Most Recent Events

  • 25 Oct 2017 Phase-I/II clinical trials in Type-1 diabetes mellitus (Adjunctive treatment) in USA (PO) (NCT03335371; 9226467)
  • 06 Sep 2017 vTv Therapeutics plans a phase II trial for Type 1 diabetes mellitus
  • 01 Sep 2016 vTv Therapeutics completes a phase II trial in Type-2 diabetes mellitus (Adjunctive treatment) in USA (PO) (NCT02405260)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top